SCALED BACK PLANS
Are Senate Democrats giving up on federal legalization?
“The tone has changed on Capitol Hill,” writes Politico, with Senate Democrats who previously said they wouldn’t accept anything but broad federal cannabis reform, are now looking instead to pass the more limited SAFE Banking Act.
That would be by adding it to another broadly supported bill—although it won’t be the America COMPETES Act.
Why the change of strategy? The pressure is on to pass some form of cannabis reform legislation before November, when Democrats risk losing control of the House and Senate. “There’s a greater sense of urgency,” said Rep. Earl Blumenauer (D-Ore.), a longtime cannabis advocate. “I think there’s a broader base of support.”
Details of Connecticut’s fentanyl-laced cannabis claims emerge
Connecticut state representatives should consider walking back claims that it had confirmed cases of cannabis laced with fentanyl, reports NBC.
- Last year, the Department of Public Health (DPH) claimed fentanyl was linked to 39 overdoses in the state. The people involved said they had only used cannabis
- In fall of 2021, the DPH said they had lab-tested and confirmed samples of fentanyl-laced marijuana
- The federal High Intensity Drug Trafficking Areas (HIDTA) investigated further, and found that not only was it unclear if people had actually overdosed from cannabis-smoking only and that police had found just one sample with fentanyl on it through five months of research, and that 30 0f 39 people who overdosed had previously used opioids
- HIDTA concluded the cannabis sample wasn’t laced, but that the dealer had unintentionally tainted the cannabis by using the same equipment to handle both drugs
HIDTA drug intelligence officer Robert Lawlor Jr. warned that while the contamination was unintentional, it could happen again. “While this may be isolated,” he said, “this could very easily happen, this could very easily have happened before, it can very easily happen again.”
Organigram to pay out $2.3 million in settlement on pesticide class action
New Brunswick-based Organigram proposed a $2.3 million settlement on Friday for a class action filed against the company alleging it used non-compliant pesticides, per CBC.
- There were two recalls of medical cannabis products in 2016 and 2017 after testing revealed “trace” quantities of bifenazate, malathion and myclobutanil
- Halifax resident Dawn Rae Downton said she had experienced “nausea, dizziness and headaches,” and they had gone away after stopping use of Organigram products
- While that case was unsuccessful, Organigram agreed to pay out a settlement to anyone who had bought the recalled products
The settlement is contingent on Supreme Court of Nova Scotia approval. “I’m glad it finally is over, or finally seems to be over,” Downton said.
CLEAR THE BOARD
Akanda shareholders scrap almost its entire board
A group of “concerned shareholders” with a 54% stake in British-based Akanda terminated every member of its board of directors on Thursday except for the CEO, per BusinessCann.
The group was led by David Jenkins, who had earlier expressed concern about the “lack of oversight and strategic direction” of the Nasdaq-traded company. Harvinder Singh, Mohsen Rahimi, Jatinder Dhaliwal and Kathryn Field will fill the roles.
“As a long-term investor in Akanda, I wish to see Akanda managed prudently and professionally, with a view to the long-term best interests of the corporation,” Jenkins said. “I am grateful for the support of my fellow shareholders who shared my concerns, and I look forward to a brighter future for all Akanda shareholders.”
Read the full article here